Cardiovascular Journal of Africa: Vol 32 No 6 (NOVEMBER/DECEMBER 2021)

CARDIOVASCULAR JOURNAL OF AFRICA • Volume 32, No 6, November/December 2021 338 AFRICA with longstanding persistent atrial fibrillation undergoing extended pulmonary vein antrum isolation: Results from a randomized study (SPECULATE). Heart Rhythm 2015; 12 (3): 477–483. 99. Wu G, Jiang H, Huang C, Yang B, Huang H, Wang Y, et al . Effects of antiarrhythmic drug use on atrial fibrillation recurrence in atrial fibril- lation patients post circumferential pulmonary vein ablation. Zhonghua Xin Xue Guan Bing Za Zhi . 2008; 36 (7): 623–626. 100. Turco P, De Simone A, La Rocca V, Iuliano A, Capuano V, Astarita C, et al . Antiarrhythmic drug therapy after radiofrequency catheter abla- tion in patients with atrial fibrillation. Pacing Clin Electrophysiol 2007; 30 (Suppl 1): S112–115. 101. Zhang X-D, Gu J, Jiang W-F, Zhao L, Zhou L, Wang Y-L, et al . Optimal rhythm-control strategy for recurrent atrial tachycardia after catheter ablation of persistent atrial fibrillation: a randomized clinical trial. Eur Heart J 2014; 35 (20): 1327–1334. 102. Pollak PT. Clinical organ toxicity of antiarrhythmic compounds: Ocular and pulmonary manifestations. Am J Cardiol 1999; 84 (9A): 37R–45R. 103. Amiodarone Trials Meta-Analysis Investigators. Effect of prophylac- tic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Lancet 1997; 350 (9089): 1417–1424. 104. Physicians’ Desk Reference . Montvale, NJ: Medical Economics Co, 2002. 105. Kaufman ES, Zimmermann PA, Wang T, Dennish GW, Barrell PD, Chandler ML, et al . Risk of proarrhythmic events in the atrial fibrilla- tion follow-up investigation of rhythm management (AFFIRM) study: A multivariate analysis . J Am Coll Cardiol 2004; 44 (6): 1276–1282. 106. Goldschlager N, Epstein AE, Naccarelli G, Olshansky B, Singh B. Practical guidelines for clinicians who treat patients with amiodarone. Arch Intern Med 2000; 160 (12): 1741–1748. 107. Babatin M, Lee S, Pollak P. Amiodarone Hepatotoxicity. Curr Vasc Pharmacol 2008; 6 (3): 228–236. 108. Epstein AE, Olshansky B, Naccarelli GV, Kennedy JI, Murphy EJ, Goldschlager N. Practical management guide for clinicians who treat patients with amiodarone. Am J Med 2016; 129 (5): 468–475. 109. Mäntyjärvi M, Tuppurainen K, Ikäheimo K. Ocular side effects of amiodarone. Surv Ophthalmol 1998; 42 (4): 360–366. 110. Cheng HC, Yeh HJ, Huang N, Chou YJ, Yen MY, Wang AG. Amiodarone-associated optic neuropathy a nationwide study. Ophthalmology 2015; 122 (12): 2553–2559. 111. Coulter DM, Edwards IR, Savage RL. Survey of neurological problems with amiodarone in the New Zealand Intensive Medicines Monitoring Programme. N Z Med J 1990; 103 (885): 98–100. 112. Orr CF, Ahlskog JE. Frequency, characteristics, and risk factors for amiodarone neurotoxicity. Arch Neurol 2009; 66 (7): 865–869. 113. Vranckx P, Valgimigli M, Heidbuchel H. The significance of drug– drug and drug–food interactions of oral anticoagulation. Arrhythmia Electrophysiol Rev 2018; 7 (1): 55–61. 114. 113. Lupercio F, Romero J, Peltzer B, Maraboto C, Briceno D, Villablanca P, et al . Efficacy and safety outcomes of direct oral antico- agulants and amiodarone in patients with atrial fibrillation. Am J Med 2018; 131 (5): 573. 115. Vassallo P, Trohman RG. Prescribing amiodarone: An evidence-based review of clinical indications. J AmMed Assoc 2007; 298 (11): 1312–1322. 116. Steinberg BA, Hellkamp AS, Lokhnygina Y, Halperin JL, Breithardt G, Passman R, et al. Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: Results from the ROCKET AF trial. Heart Rhythm 2014; 11 (6): 925–932. 117. Wan Y, Heneghan C, Perera R, Roberts N, Hollowell J, Glasziou P, et al . Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: A systematic review. Circ Cardiovasc Qual Outcomes 2008; 1 (2): 84–91. 118. Andersen SS, Hansen ML, Gislason GH, Schramm TK, Folke F, Fosbøl E, et al . Antiarrhythmic therapy and risk of death in patients with atrial fibrillation: a nationwide study. Europace 2009; 11 (7): 886–891. 119. Park HS, Kim YN. Adverse effects of long-term amiodarone therapy. Korean J Intern Med 2014; 29 (5): 571–573. 120. Ullal AJ, Than CT, Fan J, Schmitt S, Perino AC, Kaiser DW, et al . Amiodarone and risk of death in contemporary patients with atrial fibrillation: Findings from the Retrospective Evaluation and Assessment of Therapies in AF study. Am Heart J 2015; 170 (5): 1033–1041.